Japanese lawmakers are stepping in to Diovan investigation
Members of Japan’s Diet (Congressmen) have formed a bipartisan study group to examine Swiss drug major Novartis’ (NOVN: VX) now off-patent blockbuster blood pressure drug Diovan (valsartan) conflict of interest trial (The Pharma Letter July 15), reports TPL’s local analyst.
The voluntary group of lawmakers scheduled a meeting in the Diet on October 26 and called officials of the Ministry of Health, Labor and Welfare (MHLW) to explain its interim report on the Diovan scandal compiled last week.
The lawmakers are focusing on defectiveness of the system for “investigator initiated trials.” The MHLW in 2003 institutionalized the investigator initiated trials that should be conducted by medical doctors without sponsorship from pharmaceutical companies. In order to promote the independent trials, the Ministry in 2005 set out various guidelines including one for conflict of interest.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze